{"id":217462,"date":"2019-07-30T15:15:38","date_gmt":"2019-07-30T09:45:38","guid":{"rendered":"https:\/\/www.scconline.com\/blog\/?p=217462"},"modified":"2019-07-30T14:51:35","modified_gmt":"2019-07-30T09:21:35","slug":"pfizer-to-combine-off-patent-drug-business-with-mylan","status":"publish","type":"post","link":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","title":{"rendered":"Pfizer to combine off-patent drug business with Mylan"},"content":{"rendered":"<p style=\"text-align: justify;\">As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker.<\/p>\n<p style=\"text-align: justify;\">Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%.<\/p>\n<p style=\"text-align: justify;\"><em>&#8220;Combined company, which will sell Mylan\u2019s EpiPen and Pfizer\u2019s Viagra, will be domiciled in the U.S. The deal will be structured in what\u2019s known as a reverse Morris trust, with Pfizer\u2019s Upjohn business divested and then combined with Mylan.&#8221;<\/em><\/p>\n<p style=\"text-align: justify;\">It has been further reported that, New Pfizer venture will focus on drugs where exclusivity has expired. It will combine generic medicines, often made by different companies than the original drug, with off-patent drugs, which Pfizer used to sell as key brands before their patent protection ended.<\/p>\n<hr \/>\n<p>[Source: CNBC]<\/p>\n<p style=\"text-align: right;\">[Image Credits: Financial Express]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker. Pfizer shareholders would own <\/p>\n","protected":false},"author":8808,"featured_media":217463,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[8051,2],"tags":[36838,36840,36839,36837],"class_list":["post-217462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business_news","category-news","tag-mylan","tag-new-venture","tag-off-patent-drug","tag-pfizer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.4 (Yoast SEO v26.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pfizer to combine off-patent drug business with Mylan | SCC Times<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer to combine off-patent drug business with Mylan\" \/>\n<meta property=\"og:description\" content=\"As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker. Pfizer shareholders would own\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\" \/>\n<meta property=\"og:site_name\" content=\"SCC Times\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/scc.online\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-30T09:45:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1330\" \/>\n\t<meta property=\"og:image:height\" content=\"887\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Bhumika Indulia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bhumika Indulia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\",\"name\":\"Pfizer to combine off-patent drug business with Mylan | SCC Times\",\"isPartOf\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg\",\"datePublished\":\"2019-07-30T09:45:38+00:00\",\"author\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage\",\"url\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg\",\"contentUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg\",\"width\":1330,\"height\":887},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.scconline.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer to combine off-patent drug business with Mylan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#website\",\"url\":\"https:\/\/www.scconline.com\/blog\/\",\"name\":\"SCC Times\",\"description\":\"Bringing you the Best Analytical Legal News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.scconline.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a\",\"name\":\"Bhumika Indulia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg\",\"contentUrl\":\"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg\",\"caption\":\"Bhumika Indulia\"},\"url\":\"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer to combine off-patent drug business with Mylan | SCC Times","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","og_locale":"en_US","og_type":"article","og_title":"Pfizer to combine off-patent drug business with Mylan","og_description":"As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan&#8211; a generic drugmaker. Pfizer shareholders would own","og_url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","og_site_name":"SCC Times","article_publisher":"https:\/\/www.facebook.com\/scc.online\/","article_published_time":"2019-07-30T09:45:38+00:00","og_image":[{"width":1330,"height":887,"url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","type":"image\/jpeg"}],"author":"Bhumika Indulia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Bhumika Indulia","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","url":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/","name":"Pfizer to combine off-patent drug business with Mylan | SCC Times","isPartOf":{"@id":"https:\/\/www.scconline.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage"},"image":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage"},"thumbnailUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","datePublished":"2019-07-30T09:45:38+00:00","author":{"@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a"},"breadcrumb":{"@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#primaryimage","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","width":1330,"height":887},{"@type":"BreadcrumbList","@id":"https:\/\/www.scconline.com\/blog\/post\/2019\/07\/30\/pfizer-to-combine-off-patent-drug-business-with-mylan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.scconline.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Pfizer to combine off-patent drug business with Mylan"}]},{"@type":"WebSite","@id":"https:\/\/www.scconline.com\/blog\/#website","url":"https:\/\/www.scconline.com\/blog\/","name":"SCC Times","description":"Bringing you the Best Analytical Legal News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.scconline.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/919ec47cc1b871b362af05740398033a","name":"Bhumika Indulia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.scconline.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg","contentUrl":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/Me-150x150.jpg","caption":"Bhumika Indulia"},"url":"https:\/\/www.scconline.com\/blog\/post\/author\/editor_1\/"}]}},"jetpack_featured_media_url":"https:\/\/www.scconline.com\/blog\/wp-content\/uploads\/2019\/07\/pfizer.jpg","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":66051,"url":"https:\/\/www.scconline.com\/blog\/post\/2016\/09\/02\/benefit-of-safe-harbor-provision-can-be-granted-only-to-divisional-patent-applications-and-not-to-continuation-in-part-applications\/","url_meta":{"origin":217462,"position":0},"title":"Benefit of &#8216;safe harbor&#8217; provision can be granted only to divisional patent applications and not to &#8216;continuation in part&#8217; applications","author":"Saba","date":"September 2, 2016","format":false,"excerpt":"United States Court of Appeals for the Federal Circuit: Chief Judge Prost, Bryson and Hughes, Circuit Judges ruled on a case involving patent protection of a product by Pfizer Asia Pacific (used as Pfizer ahead) used for the treatment of pain and inflammation without the harmful side effects associated with\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/09\/US-Court-of-Appeals-for-Federal-Circuit.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/09\/US-Court-of-Appeals-for-Federal-Circuit.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/09\/US-Court-of-Appeals-for-Federal-Circuit.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/09\/US-Court-of-Appeals-for-Federal-Circuit.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2016\/09\/US-Court-of-Appeals-for-Federal-Circuit.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":247017,"url":"https:\/\/www.scconline.com\/blog\/post\/2021\/04\/13\/how-the-vax-was-won-part-2-follow-the-money\/","url_meta":{"origin":217462,"position":1},"title":"How the Vax was won | Part 2: Follow the money","author":"Bhumika Indulia","date":"April 13, 2021","format":false,"excerpt":"by Shantanu Mukherjee\u2020 Cite as: 2021 SCC OnLine Blog Exp 25","rel":"","context":"In &quot;Op Eds&quot;","block_context":{"text":"Op Eds","link":"https:\/\/www.scconline.com\/blog\/post\/category\/op-ed\/legal-analysis\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/MicrosoftTeams-image-64.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/MicrosoftTeams-image-64.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/MicrosoftTeams-image-64.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/MicrosoftTeams-image-64.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/04\/MicrosoftTeams-image-64.jpg?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":248824,"url":"https:\/\/www.scconline.com\/blog\/post\/2021\/05\/27\/federal-court-of-canada-upholds-validity-of-pfizers-pneumococcal-vaccine-patents-two-formulation-patents-held-invalid\/","url_meta":{"origin":217462,"position":2},"title":"Federal Court of Canada upholds validity of Pfizer\u2019s pneumococcal vaccine patents; Two Formulation patents held invalid","author":"Editor","date":"May 27, 2021","format":false,"excerpt":"Federal Court of Canada: The Bench of Gagn\u00e9, Associate CJ., upheld the validity of one pneumococcal vaccine patents pertaining to Prevnar 13 owned by Pfizer\u2019s Wyeth LLC while held the other two patents invalid. Finally, if the Court were to side with Wyeth on the construction of Claim 1, the\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/05\/Federal-Court-of-Canada.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/05\/Federal-Court-of-Canada.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/05\/Federal-Court-of-Canada.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/05\/Federal-Court-of-Canada.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/www.scconline.com\/blog\/wp-content\/uploads\/2021\/05\/Federal-Court-of-Canada.png?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":241517,"url":"https:\/\/www.scconline.com\/blog\/post\/2020\/12\/31\/subject-expert-committee-sec-meets-to-consider-emergency-use-authorisation-request-from-pfizer-sii-and-bharat-biotech\/","url_meta":{"origin":217462,"position":3},"title":"Subject Expert Committee (SEC) meets to consider Emergency Use Authorisation request from Pfizer, SII and Bharat Biotech","author":"Bhumika Indulia","date":"December 31, 2020","format":false,"excerpt":"The Subject Expert Committee (SEC) in the Central Drugs Standard Control Organisation (CDSCO) to consider the Emergency Use Authorisation (EUA) request of Pfizer, Serum Institute of India (SII) and Bharat Biotech Pvt. Ltd. Further time was requested on behalf of Pfizer. The additional data and information presented by SII and\u2026","rel":"","context":"In &quot;Hot Off The Press&quot;","block_context":{"text":"Hot Off The Press","link":"https:\/\/www.scconline.com\/blog\/post\/category\/news\/hot_off_the_press\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":18422,"url":"https:\/\/www.scconline.com\/blog\/post\/2015\/10\/08\/glenmark-restrained-from-manufacturing-and-selling-its-anti-diabetes-drugs\/","url_meta":{"origin":217462,"position":4},"title":"Glenmark restrained from manufacturing and selling its anti-diabetes drugs","author":"Sucheta","date":"October 8, 2015","format":false,"excerpt":"Delhi High Court: In granting permanent injunction to US drug company Merck Sharp and Dohme (MSD), the Court restrained Indian firm Glenmark Pharmaceuticals from manufacturing and selling its anti-diabetes drugs \"Zita\" and \"Zita-Met\", saying it has infringed patent of the plaintiff. The US drug maker in its plea had sought\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":27731,"url":"https:\/\/www.scconline.com\/blog\/post\/2015\/11\/30\/erlocip-cancer-treating-drug-manufactured-by-cipla-found-infringing-patent-of-swiss-pharmaceutical-company\/","url_meta":{"origin":217462,"position":5},"title":"\u2018Erlocip\u2019 cancer treating drug manufactured by Cipla, found infringing patent of Swiss pharmaceutical company","author":"Sucheta","date":"November 30, 2015","format":false,"excerpt":"Delhi High Court: While addressing to the issue of patent violation, the Court concluded that Cipla (Defendant) was infringing on Swiss pharmaceutical company Hoffman-La Roche's (Plaintiff) patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva. Cipla\u2019s drug named Erlocip, used for treatment of non-small cell lung\u2026","rel":"","context":"In &quot;Case Briefs&quot;","block_context":{"text":"Case Briefs","link":"https:\/\/www.scconline.com\/blog\/post\/category\/casebriefs\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/217462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/users\/8808"}],"replies":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/comments?post=217462"}],"version-history":[{"count":0,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/posts\/217462\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media\/217463"}],"wp:attachment":[{"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/media?parent=217462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/categories?post=217462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.scconline.com\/blog\/wp-json\/wp\/v2\/tags?post=217462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}